Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Coverage Initiated at Royal Bank Of Canada

Analysts at Royal Bank Of Canada started coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a report issued on Friday, Marketbeat reports. The firm set an “outperform” rating and a $40.00 price target on the stock. Royal Bank Of Canada’s target price suggests a potential upside of 61.62% from the company’s current price.

Several other research firms have also weighed in on DMRA. UBS Group began coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They issued a “buy” rating and a $45.00 target price on the stock. Lifesci Capital upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, February 2nd. Guggenheim reiterated a “buy” rating and issued a $40.00 target price (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Evercore began coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 target price on the stock. Finally, Leerink Partners assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Wednesday, January 7th. They issued an “outperform” rating and a $46.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.40.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of DMRA stock opened at $24.75 on Friday. Damora Therapeutics, Inc. Common Stock has a 52-week low of $2.45 and a 52-week high of $38.33. The stock has a market cap of $1.49 billion, a PE ratio of -2.05 and a beta of 1.59. The firm’s 50 day moving average price is $27.04 and its two-hundred day moving average price is $22.79.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at about $76,000. Virtu Financial LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at about $49,000. Connective Capital Management LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at about $100,000. Sigma Planning Corp bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at about $334,000. Finally, Geode Capital Management LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at about $266,000. 14.20% of the stock is currently owned by institutional investors and hedge funds.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.